Preparation for EU JCA and JSC is Key to Ensure Optimal Readiness
The Health Technology Assessment (HTA) landscape in Europe is undergoing a significant shift, with the introduction of the Joint Clinical Assessment (JCA) in 2025, initially for oncology products and advanced therapy medicinal products, with expansion to orphan products in 2028 and all new medicines in 2030.
We have a track record of forming long-term partnerships with our clients, from early-stage strategic planning through to end-stage reimbursement submission support. Our experience in European market access includes Scientific Advice, national and pan-national reimbursement dossiers, including BeNeLuxAIr and EUnetHTA, and global- and European-focussed value dossiers. Drawing on our experience, and in collaboration with our Evidence Development teams, we have been actively preparing for the introduction of the JCA.
Our dedicated EU JCA Taskforce have been rolling out trainings across the company to up-skill teams and ensure we are on top of the latest communications regarding the implementation of the JCA
Our teams across Value and Access and Evidence Development have been reflecting on the key challenges and opportunities the JCA brings. Our recent articles can be found below
We appreciate a lot remains unknown around how EU JCA will work in practice. We are aiming to understand our clients’ questions and concerns around EU JCA, and using these as focus areas for our research
